|Articles|October 1, 2018

Is the Price Right Figure 2

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

President Trump must still approve the Defense Bill, which the Biosecure Act is included in. Credit: Stock.adobe.com. Lane Erickson.

Senate Passes Biosecure Act

ByMike Hollan

December 18th 2025

Novo Nordisk Submits NDA to FDA for CagriSema

ByNicholas Jacobus

December 18th 2025

Image Credit: Adobe Stock Images/hafakot

The End of the Rebate Era? What HR Leaders and Pharmacy Consultants Need to Know About Biosimilars

ByBridget Mulvenna

December 18th 2025

Four Republicans Break with House GOP to Force Vote on Extending ACA Tax Credits

ByMike Hollan

December 17th 2025

Image Credit: Adobe Stock Images/Sebastian Kaulitzki

FDA Approves GSK's Exdensur as Twice-Yearly Add-On Therapy for Severe Asthma

ByDavy James

December 17th 2025

Is the Price Right Figure 2

Newsletter

Related Content

Senate Passes Biosecure Act

Novo Nordisk Submits NDA to FDA for CagriSema

The End of the Rebate Era? What HR Leaders and Pharmacy Consultants Need to Know About Biosimilars

Four Republicans Break with House GOP to Force Vote on Extending ACA Tax Credits

FDA Approves GSK's Exdensur as Twice-Yearly Add-On Therapy for Severe Asthma

Trending on PharmExec

Novo Nordisk Submits NDA to FDA for CagriSema

The End of the Rebate Era? What HR Leaders and Pharmacy Consultants Need to Know About Biosimilars

Eli Lilly Announces Topline Results From Phase III Trial Studying Oral GLP-1 Therapy Orforglipron

Senate Passes Biosecure Act

Pharmaceutical Executive Daily: Pfizer's Stock Drops Following 2026 Revenue Projections Release